Jefferies resumes Genmab at 'buy' on a 'catalyst-rich 2026'

Genmab A/S

17/02/2026 08:25

** Jefferies resumes coverage of Danish biotechnology firm Genmab GMAB.CO at "buy", citing a catalyst-rich 2026 that should secure long-term growth

** The broker says Genmab's recent acquisitions have successfully mitigated risks to long-term value linked to the expected decline of royalties from cancer drug Darzalex after 2029

** The brokerage sees upside in pipeline asset Peto for head and neck cancer, noting a potential $3.5 billion in peak sales from a setting the market currently overlooks

** Readouts for lymphoma drug Epkinly and Rina-S, an antibody-drug conjugate (ADC), could unlock a combined $3.4 billion in peak sales, with Rina-S 1-2 years ahead of rivals, Jefferies says

** Out of the 20 analysts covering the stock, 11 rate it "strong buy"/"buy", seven "hold", two "sell"/"strong sell" - LSEG data

(Reporting by Vera Dvorakova)

((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))